drugset / Trial / NCT03911414

A Clinical Trial Via Telepsychiatry of Treatments for the Management of Emotional Dysregulation in Youth

NCT03911414

Phase 4 Completed 27 enrolled Massachusetts General Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

This study consists of a 6-week, open-label, randomized clinical trial study to compare efficacy and tolerability of the natural treatments omega-3 fatty acids, inositol, and N-acetylcysteine (NAC) in the treatment of mood dysregulation in children and adolescents (ages 5-17). Subjects will be randomized to one of two arms: 1) omega-3 fatty acids plus inositol or 2) NAC.

Timeline

Start
2019-06-18
Primary completion
2024-12-04
Completion
2024-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Inositol Small molecule 1000 mg
Subject Inositol Small molecule 2000 mg
Subject N-acetylcysteine Small molecule 1800 mg
Subject N-acetylcysteine Small molecule 2400 mg
Subject N-acetylcysteine Small molecule 2700 mg
Subject Omega-3 fatty acids Unknown 1020 mg

Indications